DOI: 10.1136/bmj.s325 Never miss a breakthrough: Join the SciTechDaily newsletter
24, 2026 /PRNewswire/ --Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy and Ozempic , respectively, from the current list price
The combination of significant caloric restriction (from appetite suppression) and no resistance training leads to muscle loss alongside fat loss
This product goal is to fill the gap between the two
It upregulates growth factors including VEGF and EGF